Full Therapeutic Dose of Enoxaparin for ACS
For patients admitted with acute coronary syndrome (ACS), enoxaparin (Clexane) should be administered at therapeutic (full) dose, not prophylactic dose. The standard therapeutic regimen is 1 mg/kg subcutaneously every 12 hours, with dose adjustment to 1 mg/kg once daily if creatinine clearance is <30 mL/min 1.
Dosing Algorithm Based on Clinical Context
Initial Therapy (Medical Management)
- Standard dose: 1 mg/kg subcutaneously every 12 hours
- Renal impairment (CrCl <30 mL/min): Reduce to 1 mg/kg once daily subcutaneously 1
- Continue until revascularization or hospital discharge
If Patient Proceeds to PCI
The dosing depends on timing of last subcutaneous dose:
- Last dose given <8 hours before PCI: No additional enoxaparin needed 1
- Last dose given 8-12 hours before PCI OR only 1 dose given: Give 0.3 mg/kg IV bolus 1
- No prior enoxaparin: Give 0.5-0.75 mg/kg IV bolus 1
With Fibrinolytic Therapy (STEMI)
- Age <75 years: 30 mg IV bolus, then 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first 2 doses) 1
- Age ≥75 years: No bolus, 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for first 2 doses) 1
- CrCl <30 mL/min (any age): 1 mg/kg subcutaneously every 24 hours 1
Rationale for Therapeutic Dosing
The 2025 ACC/AHA/SCAI guidelines explicitly recommend therapeutic anticoagulation for ACS patients, with enoxaparin listed as a Class 2b recommendation as an alternative to unfractionated heparin at the time of PCI to reduce ischemic events 1. Prophylactic dosing (40 mg once daily) is intended for venous thromboembolism prevention, NOT for arterial thrombosis in ACS 2.
The therapeutic dose of 1 mg/kg every 12 hours has been validated in multiple trials for ACS management and provides adequate anti-factor Xa levels to prevent recurrent ischemic events 3. This is fundamentally different from the prophylactic dose of 40 mg daily used for DVT prevention in hospitalized patients 2.
Critical Safety Considerations
Bleeding Risk with Excess Dosing
Avoid overdosing: Nearly 19% of patients in real-world practice receive excess doses (>10 mg above recommended), which significantly increases major bleeding (OR 1.43) and mortality (OR 1.35) 4. This most commonly occurs in:
- Elderly patients (median age 78 years)
- Lower body weight patients
- Female patients 4
Always calculate the actual dose based on patient weight rather than using fixed dosing.
Renal Function Monitoring
Patients with significant renal impairment (serum creatinine >150 µmol/L or CrCl <30 mL/min) are at risk for enoxaparin bioaccumulation 5. Mandatory dose reduction to once daily dosing in this population 1.
Timing Considerations
Premature discontinuation of anticoagulation causes rebound thrombin activity with greatest reinfarction risk in the first 4-8 hours 1. Continue therapeutic anticoagulation until definitive revascularization is performed.
Drug Interactions
Increased bleeding risk occurs with:
- Clopidogrel (OR 7.70 for major bleeding) 5
- NSAIDs or other antiplatelet agents (OR 2.38) 5
- GP IIb/IIIa inhibitors 6
Common Pitfalls to Avoid
Using prophylactic dose (40 mg daily): This is inadequate for ACS and appropriate only for VTE prophylaxis 2
Failure to document body weight: 9% of patients in one study had no weight documentation, leading to inappropriate dosing 5
Not adjusting for renal function: Failure to reduce dose in CrCl <30 mL/min increases bleeding risk substantially 1, 5
Giving additional enoxaparin at PCI when last dose was <8 hours prior: This causes excess anticoagulation 1
Using in elderly without dose consideration: Age is an independent risk factor for bleeding (OR 1.57 per decade) 5, though the dose remains 1 mg/kg every 12 hours unless renal impairment exists
The evidence strongly supports therapeutic dosing of enoxaparin in ACS to reduce mortality and recurrent ischemic events, with careful attention to weight-based dosing and renal function to minimize bleeding complications.